Intel Stock Gets Slammed. Is This a Buy-the-Dip Moment?

Intel reported Q4 revenue of $13.7 billion (down 4% YoY) and non-GAAP EPS of $0.15 (up 15% YoY), with full-year revenue at $52.9 billion essentially flat. Management warned of supply-constrained Q1, guiding revenue to $11.7–$12.7 billion (midpoint ~11% below Q4) and non-GAAP EPS of $0.00, while saying supply should improve in Q2 and beyond; data center & AI revenue rose 9% YoY to $4.7 billion. Despite healthy demand, the supply-driven near-term hit and a market cap near $230 billion with a price-to-sales above 4 leave limited room for execution misses, making the update a material negative for sentiment and stock performance unless supply and ramp execution improve.

Analysis

Market structure: Intel's Q1 supply pinch (midpoint revenue ~11% below Q4) spatially reallocates near-term AI/server demand to suppliers with available capacity — primary beneficiaries: NVDA (accelerator demand), AVGO (infrastructure ASICs) and TXN (analog/industrial resilience). Pricing power will shift short-term to any supplier who can absorb hyperscaler orders; Intel losing ~1–3ppt share in data center over a quarter is plausible. Cross-asset: expect elevated IV in INTC options, modest safe-haven flows into US Treasuries (3–6bp rally on risk-off), and mild upside pressure on wafer/chemical inputs if fabs push overtime.

Risk assessment: Tail risks include a multi-quarter Intel execution failure that accelerates share loss to NVIDIA/AMD/Broadcom (severe case: >15% DC share loss over 12 months) or a capex write-down if foundry ramps miss; regulatory export controls or a hyperscaler customer pivot could amplify losses. Time horizons: immediate (days) volatility spikes around guidance updates; short-term (weeks–months) depends on Q1 shipping cadence and Q2 ramp commentary; long-term (quarters–years) hinges on fab yield curves and gross-margin recovery. Hidden dependencies: hyperscaler order timing, third-party foundry allocation, and wafer-start cadence — watch bill-of-materials lead times and gross-capacity utilization.

Trade implications: Tactical relative-value: long NVDA or AVGO vs short INTC to express demand-consumption shift; target notional 1:1, rebalance after Intel’s Q2 update. Options: buy INTC Mar/Apr 2026 puts (5–10% OTM) as a low-cost hedge versus long AI/infra exposure; consider selling premium on INTC if IV exceeds realized by >6pts. Sector rotation: increase exposure to high-margin infrastructure names (NVDA, AVGO) and reduce cyclical, execution-dependent exposure to INTC until Q2 supply evidence.

Contrarian angles: Consensus prices a Q2 turnaround; what’s missed is the probability of execution slippage during the ramp — market implies profitability recovery (P/S>4) that requires ~20–30% margin improvement vs FY25. Reaction may be underdone on the downside if yields slip, or overdone if Intel proves supply recovery in Q2 and captures AI design wins. Historical parallel: Intel’s 2018–2021 node delays show multi-quarter share effects; if Intel meets Q2 targets, a mean reversion rally could be sharp (20–30%). Monitor wafer starts, gross margin, and hyperscaler booking cadence as high-signal metrics.

Key Decisions for Investors

• Establish a 2–3% notional long position in NVDA and/or AVGO (split 60/40) by 03/31/2026 to capture demand migrating from constrained INTC supply; target 12–18% 12-month upside, trim on 20% gains or after Intel confirms Q2 sequential revenue recovery >5% Q/Q.
• Enter a 1–1.25% notional short INTC position as a pair trade against NVDA/AVGO (1:1 notional) until Intel reports Q2 results; increase hedge if INTC fails to show sequential revenue improvement >5% in Q2 or if non-GAAP EPS remains ≤ $0.00 in Q2 guidance.
• Buy INTC Mar/Apr 2026 5–10% OTM put options equal to 0.5–1% of portfolio value as insurance against a deeper execution collapse; unwind if IV compresses by >30% or after Intel issues Q2 guide showing sequential revenue recovery and EPS > $0.10.
• Do not add to direct INTC longs unless one of the following thresholds is met: (a) P/S falls below 3.0, (b) management confirms Q2 available supply growth >=10% month-over-month and Q2 non-GAAP EPS guidance >= $0.10, or (c) gross margin expansion of >=200bps sequentially is demonstrated.